Looking to the future: diabetic neuropathy and effects of rosuvastatin on neurovascular function in diabetes models

References 

1. Cameron NE, Cotter MA. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes. 1997;46(Suppl. 2):S31–S37
2. Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia. 2001;44:1973–1988
   • MEDLINE
   • CrossRef
3. Stalker TJ, Lefer AM, Scalia R. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br. J. Pharmacol. 2001;133:406–412
   • MEDLINE
   • CrossRef
4. Li W, Asagami T, McTaggart F, Tsao PS. The novel HMG-CoA reductase inhibitor, rosuvastatin, attenuates monocyte adhesion in a murine model of hypercholesterolemia. Circulation. 2001;104(Suppl. II):II-212
5. Hermann M, Ruschitzka F, Camici G, Lüscher TF. Rosuvastatin improves endothelial dysfunction in a rat model of normocholesterolemic mineralocorticoid hypertension. Eur. Heart J. 2002;23(Suppl.):363; abstract 1939
6. Jones SP, Gibson MF, Rimmer DM, Gibson TM, Sharp BR, Lefer DJ. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J. Am. Coll. Cardiol. 2002;40:1172–1178
   • Abstract
   • Full Text
   • Full-Text PDF (250 KB)
   • CrossRef
7. Laufs U, Nickenig G, Böhm M, Gertz K. Rosuvastatin, a new HMG-CoA reductase inhibitor, up-regulates endothelial nitric oxide synthase and protects from stroke in mice. Eur. Heart J. 2002;23(Suppl.):499
8. Werner N, Priller J, Laufs U, et al.  Endothelial progenitor cells modulate vascular re-endothelialization and neointima formation. Effect of HMG CoA reductase inhibition. Eur. Heart J. 2002;23(Suppl.):500
9. Yagihashi S. Pathology and pathogenetic mechanisms of diabetic neuropathy. Diab. Metab. Rev. 1995;11:193–225
10. Sima AAF, Sugimoto K. Experimental diabetic neuropathy: an update. Diabetologia. 1999;42:773–788
    • MEDLINE
    • CrossRef
11. Cameron NE, Cotter MA. The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. Diab. Metab. Res. 1994;10:189–224
12. Greene DA, Sima AAF, Stevens MJ, Feldman EL, Lattimer SA. Complications: neuropathy, pathogenetic considerations. Diab. Care. 1902;15(192):1925
13. Cameron NE, Cotter MA. Effects of antioxidants on nerve and vascular dysfunction in experimental diabetes. Diab. Res. Clin. Pract. 1999;45:137–146
14. Ford I, Cotter MA, Cameron NE, Greaves M. The effects of treatment with α-lipoic acid or evening primrose oil on vascular hemostatic and lipid risk factors, blood flow, and peripheral nerve conduction in the streptozotocin-diabetic rat. Metabolism. 2001;50:868–875
    • Abstract
    • Full-Text PDF (219 KB)
    • CrossRef
15. Tesfaye S, Stevens L, Stephenson J, et al.  The prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM complications study. Diabetologia. 1996;39:1377–1384
    • MEDLINE
    • CrossRef
16. Watts GF, O'Brien SF, Silvester W, Millar JA. Impaired endothelium-dependent and -independent dilatation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: role of dyslipidemia. Clin. Sci. (Colch.). 1996;91:567–573
17. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 1999;48:1–9
    • MEDLINE
    • CrossRef
18. Cameron NE, Inkster ME, Nangle MR, Smith GJ, McTaggart F, Cotter MA. Effects of rosuvastatin, a new HMG-CoA reductase inhibitor, on neurovascular function in diabetic rats. Diabetes. 2001;50(Suppl. 2):A184